{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:21:17Z","timestamp":1787505677629,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40257-016-0217-1","type":"journal-article","created":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T11:55:21Z","timestamp":1470052521000},"page":"673-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Nationwide Assessment of Cause-Specific Mortality in Patients with Rosacea: A Cohort Study in Denmark"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8257-1816","authenticated-orcid":false,"given":"Alexander","family":"Egeberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Joseph F.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar H.","family":"Gislason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"issue":"5","key":"217_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jaad.2014.08.028","volume":"72","author":"AM Two","year":"2015","unstructured":"Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749\u201358 (quiz 59\u201360).","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"217_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46(4):584\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"217_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jaad.2004.01.048","volume":"50","author":"J Wilkin","year":"2004","unstructured":"Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"217_CR4","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/jid.2015.141","volume":"135","author":"T Buhl","year":"2015","unstructured":"Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1\/Th17 pathways. J Invest Dermatol. 2015;135(9):2198\u2013208.","journal-title":"J Invest Dermatol."},{"issue":"6 Suppl 1","key":"217_CR5","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jaad.2013.04.045","volume":"69","author":"M Steinhoff","year":"2013","unstructured":"Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69(6 Suppl 1):S15\u201326.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"217_CR6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jaad.2012.11.038","volume":"68","author":"LB Weinstock","year":"2013","unstructured":"Weinstock LB, Steinhoff M. Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin. J Am Acad Dermatol. 2013;68(5):875\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"217_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/MCG.0b013e3182040eb2","volume":"45","author":"LB Weinstock","year":"2011","unstructured":"Weinstock LB. Rosacea in Crohn\u2019s disease: effect of rifaximin. J Clin Gastroenterol. 2011;45(3):295\u20136.","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"217_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jaad.2015.04.028","volume":"73","author":"TC Hua","year":"2015","unstructured":"Hua TC, Chung PI, Chen YJ, Wu LC, Chen YD, Hwang CY, et al. Cardiovascular comorbidities in patients with rosacea: a nationwide case-control study from Taiwan. J Am Acad Dermatol. 2015;73(2):249\u201354.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"217_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jaad.2015.07.009","volume":"73","author":"BM Rainer","year":"2015","unstructured":"Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang S, Chien AL. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol. 2015;73(4):604\u20138.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"217_CR10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaad.2016.02.1158","volume":"75","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Hansen PR, Gislason G, Thyssen JP. Assessment of the risk of cardiovascular disease in patients with rosacea. J Am Acad Dermatol. 2016;75(2):336\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"9596","key":"217_CR11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Elm von","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"8","key":"217_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, Sorensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541\u20139.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"217_CR13","first-page":"263","volume":"46","author":"TF Andersen","year":"1999","unstructured":"Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263\u20138.","journal-title":"Dan Med Bull"},{"issue":"4","key":"217_CR14","first-page":"445","volume":"44","author":"D Gaist","year":"1997","unstructured":"Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445\u20138.","journal-title":"Dan Med Bull"},{"issue":"7 Suppl","key":"217_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1403494811399958","volume":"39","author":"K Helweg-Larsen","year":"2011","unstructured":"Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7 Suppl):26\u20139.","journal-title":"Scand J Public Health."},{"key":"217_CR16","doi-asserted-by":"crossref","unstructured":"Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Clustering of autoimmune diseases in patients with rosacea. J Am Acad Dermatol. 2016;74(4):667\u201372 e1.","DOI":"10.1016\/j.jaad.2015.11.004"},{"key":"217_CR17","unstructured":"Egeberg A, Weinstock LB, Thyssen EP, Gislason GH, Thyssen JP. Rosacea and gastrointestinal disorders. Br J Dermatol. 2016 (minor revision)."},{"issue":"7","key":"217_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cgh.2008.02.054","volume":"6","author":"A Parodi","year":"2008","unstructured":"Parodi A, Paolino S, Greco A, Drago F, Mansi C, Rebora A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759\u201364.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"217_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/2050640614559262","volume":"3","author":"A Gravina","year":"2015","unstructured":"Gravina A, Federico A, Ruocco E, Lo Schiavo A, Masarone M, Tuccillo C, et al. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. United Eur Gastroenterol J. 2015;3(1):17\u201324.","journal-title":"United Eur Gastroenterol J."},{"issue":"3","key":"217_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1365-2133.2012.11037.x","volume":"167","author":"J Spoendlin","year":"2012","unstructured":"Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study on the epidemiology of rosacea in the UK. Br J Dermatol. 2012;167(3):598\u2013605.","journal-title":"Br J Dermatol."},{"issue":"6","key":"217_CR21","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1365-2133.2005.06895.x","volume":"153","author":"MA Gupta","year":"2005","unstructured":"Gupta MA, Gupta AK, Chen SJ, Johnson AM. Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey\u2014Outpatient Department data collected by the US National Center for Health Statistics from 1995 to 2002. Br J Dermatol. 2005;153(6):1176\u201381.","journal-title":"Br J Dermatol"},{"issue":"5","key":"217_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamaneurol.2016.0022","volume":"73","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Exploring the association between rosacea and Parkinson disease: a Danish nationwide cohort study. JAMA Neurol. 2016;73(5):529\u201334.","journal-title":"JAMA Neurol."},{"issue":"6","key":"217_CR23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ana.24645","volume":"79","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Patients with rosacea have increased risk of dementia. Ann Neurol. 2016;79(6):921\u20138.","journal-title":"Ann Neurol."},{"key":"217_CR24","unstructured":"Egeberg A, Thyssen JP. Rosacea and Parkinson disease: the importance of subtype analysis [authors\u2019 reply] JAMA Neurol. 2016 [Epub ahead of print]."},{"issue":"11","key":"217_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrneurol.2015.197","volume":"11","author":"L Klingelhoefer","year":"2015","unstructured":"Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease: the gut-brain axis and environmental factors. Nat Rev Neurol. 2015;11(11):625\u201336.","journal-title":"Nat Rev Neurol."},{"issue":"14","key":"217_CR26","first-page":"1270","volume":"75","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology. 2010;75(14):1270\u20136.","journal-title":"A prospective population-based long-term study. Neurology."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0217-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-016-0217-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0217-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T14:36:13Z","timestamp":1581950173000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-016-0217-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["217"],"URL":"https:\/\/doi.org\/10.1007\/s40257-016-0217-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,1]]},"assertion":[{"value":"1 August 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Drs. Egeberg and Gislason had full access to all of the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. Study concept and design: Alexander Egeberg and Jacob Thyssen. Acquisition, analysis, and interpretation of data: Alexander Egeberg, Gunnar Gislason, and Jacob Thyssen. Drafting of the manuscript: Alexander Egeberg and Jacob Thyssen. Critical revision of the manuscript for important intellectual content: Alexander Egeberg, Joseph Fowler, Gunnar Gislason, and Jacob Thyssen. Statistical analysis: Alexander Egeberg and Gunnar Gislason. Obtained funding: Alexander Egeberg. Administrative, technical, or material support: Alexander Egeberg, Gunnar Gislason, and Jacob Thyssen. Study supervision: Alexander Egeberg, Gunnar Gislason, and Jacob Thyssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Dr. Egeberg has received research funding and\/or consultancy honoraria from Pfizer and Eli Lilly. Dr. Gislason is supported by an unrestricted research scholarship from the Novo Nordisk Foundation, and reports research grants from Pfizer, Bristol\u2013Myers Squibb, AstraZeneca, Bayer and Boehringer Ingelheim. Dr. Thyssen is supported by an unrestricted grant from the Lundbeck foundation, and has received consultancy and\/or speaker honoraria from Galderma and MEDA. Dr Fowler has no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No funding was received for the conduct of this study or the preparation of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The study was approved by the Danish Data Protection agency (ref. 2007-58-0015, int. ref. GEH-2014-018, I-suite 02736), and, in Denmark, register studies do not require approval from an ethical committee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}